Issued to AZURITY. Application is approved as submitted.
Posted by FDA
June 16, 2026Application
NDA 505b1 • 219423
Product
WIDAPLIK
Company
AZURITY
Stage
Final Decision
Assyro regulatory brief
FreeSource facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
FDA posted an approval letter for WIDAPLIK on 2026-06-16. This is the document posting date; consult the signed letter for the decision date. The source metadata identifies NDA 219423 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
This letter documents an FDA approval action: FDA approved NDA 219423 for WIDAPLIK, sponsored by AZURITY,. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
NDA 219423 is the application under which FDA issued this approval letter for WIDAPLIK to AZURITY. FDA posted the letter on June 16, 2026; the posting date is not the decision date.
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.